Tax Reform Provides Environment For M&A Surge, EY Report Says
2018 should see an increase in significant biopharma deal-making, possibly even a mega-merger, as US companies are able to repatriate offshore cash at lower tax rates.
2018 should see an increase in significant biopharma deal-making, possibly even a mega-merger, as US companies are able to repatriate offshore cash at lower tax rates.